Blair William & Co. IL Has $1.31 Million Position in Incyte Co. (NASDAQ:INCY)

Blair William & Co. IL lessened its holdings in Incyte Co. (NASDAQ:INCY) by 40.0% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 21,629 shares of the biopharmaceutical company’s stock after selling 14,445 shares during the period. Blair William & Co. IL’s holdings in Incyte were worth $1,311,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Cape Investment Advisory Inc. acquired a new position in shares of Incyte during the 4th quarter worth approximately $25,000. MFA Wealth Advisors LLC bought a new stake in shares of Incyte in the second quarter valued at approximately $26,000. Redmont Wealth Advisors LLC acquired a new stake in Incyte during the first quarter worth approximately $28,000. Riverview Trust Co bought a new position in Incyte during the 1st quarter worth $29,000. Finally, Fidelis Capital Partners LLC acquired a new position in Incyte in the 1st quarter valued at $32,000. Institutional investors own 96.97% of the company’s stock.

Insider Transactions at Incyte

In other Incyte news, EVP Barry P. Flannelly sold 8,148 shares of the company’s stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $60.00, for a total value of $488,880.00. Following the completion of the transaction, the executive vice president now directly owns 50,534 shares in the company, valued at approximately $3,032,040. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Barry P. Flannelly sold 1,306 shares of the company’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $64.19, for a total value of $83,832.14. Following the transaction, the executive vice president now owns 58,042 shares in the company, valued at approximately $3,725,715.98. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Barry P. Flannelly sold 8,148 shares of the business’s stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $60.00, for a total transaction of $488,880.00. Following the completion of the transaction, the executive vice president now owns 50,534 shares of the company’s stock, valued at $3,032,040. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 34,047 shares of company stock worth $2,225,626. Insiders own 17.50% of the company’s stock.

Incyte Stock Performance

NASDAQ:INCY opened at $64.12 on Tuesday. Incyte Co. has a twelve month low of $50.27 and a twelve month high of $70.36. The stock has a market cap of $14.40 billion, a P/E ratio of 19.43, a PEG ratio of 5.03 and a beta of 0.73. The company has a quick ratio of 1.84, a current ratio of 1.92 and a debt-to-equity ratio of 0.01. The business’s 50-day moving average price is $64.36 and its two-hundred day moving average price is $59.84.

Incyte (NASDAQ:INCY) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported ($1.82) EPS for the quarter, missing analysts’ consensus estimates of $0.78 by ($2.60). The firm had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.01 billion. Incyte had a net margin of 2.52% and a return on equity of 0.75%. The firm’s revenue was up 9.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.77 EPS. As a group, equities analysts predict that Incyte Co. will post 0.67 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on INCY. Bank of America raised their price target on Incyte from $66.00 to $68.00 and gave the stock a “neutral” rating in a research report on Monday, September 16th. Guggenheim raised their target price on shares of Incyte from $86.00 to $92.00 and gave the company a “buy” rating in a report on Monday, September 16th. Truist Financial reaffirmed a “hold” rating and set a $74.00 price target (down previously from $83.00) on shares of Incyte in a report on Wednesday, September 18th. Citigroup increased their price target on shares of Incyte from $80.00 to $88.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Incyte from $59.00 to $61.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $73.24.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.